AZ And Merck Notch Another Win For Koselugo In Adults With NF1

The MEK inhibitor, already approved for pediatric patients with the rare condition neurofibromatosis type 1, showed benefits for adults in a Phase III trial.

(Shutterstock)

More from Clinical Trials

More from Rare Diseases